FDA Classifies Pharmacogenetic Assessment System into Class II Special Controls

Summary

The US Food and Drug Administration (FDA) is classifying the pharmacogenetic assessment system into Class II, special controls, to ensure safety and effectiveness, and to reduce regulatory burdens, ultimately enhancing patients' access to innovative devices.